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Abstract
Background: Periodontal disease is an inflammatory disease of the tissues supporting the teeth. Women who have
periodontal disease while pregnant may be at risk of adverse pregnancy outcomes. Although the association
between periodontal disease and adverse pregnancy outcomes has been addressed in a considerable number of
systematic reviews and meta-analyses, there are important differences in the conclusions of these reviews.
Systematic reviews assessing the effectivity of various therapeutic interventions to treat periodontal disease during
pregnancy to try and reduce adverse pregnancy outcomes have also arrived at different conclusions. We aim to
provide a systematic overview of systematic reviews comparing the frequency of adverse pregnancy outcomes
between women with and without periodontal disease and/or evaluating the effect of preventive and therapeutic
interventions for periodontal disease before or during pregnancy on adverse pregnancy outcomes.
Methods: We will include systematic reviews reporting on studies comparing adverse pregnancy outcomes: (i)
between women with or without periodontal disease before (<6 months) or during pregnancy and/or (ii) according
to preventive or therapeutic interventions for periodontal disease. Eligible interventions include (combinations of)
the following: oral hygiene education, use of antibiotics, subgingival scaling, and root planing. For preventive and/
or therapeutic reviews, the following comparisons will be considered: no intervention, a placebo intervention, or an
alternative intervention. Our primary adverse pregnancy outcomes of interests are maternal mortality, preterm
delivery, and perinatal mortality. Two reviewers will independently identify eligible published and unpublished
systematic reviews from six electronic databases and using hand searching of reference lists and citations. Data
items extracted from included systematic reviews are based on the Cochrane Effective Practice and Organization of
Care checklist and the preferred reporting items for systematic review and meta-analysis (PRISMA) statement. In our
narrative data synthesis, we will consider risk of bias of individual reviews, focusing mainly on the conclusions of
the highest quality reviews using the assessment of multiple systematic reviews (AMSTAR) checklist. Disagreements
during search, selection, data extraction, and risk of bias assessment will be resolved through discussion and/or
consultation of a third reviewer.
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Background
Periodontal disease is an inflammatory disease of the tis-
sues supporting the teeth. In the USA, 65 million adults
over the age of 30 years suffer from periodontal disease
[1]. Five to seventy percent of adults worldwide have
periodontal disease, depending on the geographical loca-
tion and disease definition used [2]. Women who have
periodontal disease while pregnant—an estimated one in
five pregnant women—have been reported to be at in-
creased risk of adverse pregnancy outcomes [3, 4].
The adverse pregnancy outcome most often associated
with periodontal disease is preterm delivery [4]. A large
prospective study by Offenbacher et al. showed that the
prevalence of extremely preterm delivery (<28 weeks
gestation) was increased tenfold in women with
moderate-severe periodontal disease as compared to
women without periodontal disease: 11.1 versus 1.1 %,
respectively [5]. Other adverse pregnancy outcomes that
have been associated with periodontal disease include
low birth weight [5], preeclampsia [6, 7], and being small
for gestational age (SGA) [8]. Although the association
between periodontal disease and adverse pregnancy out-
comes has been investigated in a considerable number
of systematic reviews and meta-analyses, there are im-
portant differences in the conclusions of these reviews
[9–12]. In line with this, systematic reviews assessing the
effectiveness of therapeutic interventions to treat peri-
odontal disease during pregnancy to try and reduce ad-
verse pregnancy outcomes have arrived at different
conclusions [13–15].
Given the global disease burden of both periodontal dis-
ease and the various adverse pregnancy outcomes that have
been associated with it [16–18], a better understanding of
the relationship between periodontal disease and adverse
pregnancy outcomes, as well as the potential effectiveness
of preventive and therapeutic interventions, is clearly
needed in order to provide recommendations for clinical
practice as well as guide future research into the possible
underlying causal mechanisms.
Objectives
We therefore aim to comprehensively assess the avail-
able evidence on this topic via a systematic overview of
systematic reviews to address the following objectives:
 Summarize systematic reviews comparing the
frequency of adverse pregnancy outcomes between
women with and without periodontal disease
 Summarize systematic reviews evaluating the effect
of preventive and therapeutic interventions for
periodontal disease before or during pregnancy on
adverse pregnancy outcomes.
Methods/design
The research methods follow the preferred reporting
items for systematic review and meta-analysis protocols
(PRISMA-P; see also PRISMA-P checklist: Additional
file 1) [19, 20]. Our study is registered with the PROS-
PERO prospective register of systematic reviews
(CRD42015030132).
Eligibility criteria
Studies will be selected according to the criteria outlined
below.
Study characteristics
Study design
We will include systematic reviews: literature reviews
that use a systematic search strategy to find relevant re-
search aimed at answering a clearly defined clinical
question. We will not include non-systematic narrative
reviews, individual studies, case reports, case series, edi-
torials, or clinical guidelines publications. Included re-
views must describe a systematic search strategy and
include data from either of the following: randomized
controlled trials (RCTs, including cluster RCTs), con-
trolled (non-randomized) clinical trials (CCTs) or cluster
trials, interrupted time series (ITS) studies, (un)con-
trolled before-and-after (CBA) studies, prospective or
retrospective cohort studies, cross-sectional studies, and
case-control or nested case-control studies.
Participants
We will include systematic reviews reporting on stud-
ies in preconceptional or pregnant women with peri-
odontal disease identified before (<6 months) or
during pregnancy. Periodontal disease includes gingi-
vitis (gingival inflammation) and periodontitis (gingi-
vitis with gingival recession accompanied by loss of
Vanterpool et al. Systematic Reviews  (2016) 5:16 Page 2 of 6
connective tissue and alveolar bone) [21, 22] and is
usually identified by at least one of the following clin-
ical periodontal indexes: clinical attachment loss, clin-
ical attachment level, probing depth, or bleeding on
probing [23].
Interventions
Systematic reviews covering any intervention(s)
aimed at prevention and/or treatment of periodontal
disease before (<6 months) or during pregnancy are
eligible for inclusion. Eligible interventions include
(combinations of ) the following: oral hygiene educa-
tion, use of antibiotics, subgingival scaling, and root
planing. Considering that we are also interested in
the association between periodontal disease and ad-
verse pregnancy outcomes irrespective of treatment,
systematic reviews not covering any intervention
may also be eligible for inclusion provided they re-
port on this association.
Comparisons
To evaluate the risk of adverse pregnancy outcomes
in women with periodontal disease, we will include
systematic reviews comparing the risk of adverse
pregnancy outcomes between women with periodontal
disease and women without periodontal disease before
(<6 months) or during pregnancy. To evaluate the ef-
fect of preventive and/or therapeutic interventions for
periodontal disease on adverse pregnancy outcomes,
we will include systematic reviews comparing the risk
of adverse pregnancy outcomes among women with
periodontal disease during this period according to
whether or not they received an intervention. The
following will be considered as comparisons: no inter-
vention, a placebo intervention, or an alternative
intervention.
Outcomes and prioritization
For the purpose of this overview, we define adverse
pregnancy outcomes as a complication of pregnancy,
labor, and delivery or post-partum period (up to 6 weeks
after delivery) that is associated with maternal, fetal,
and/or neonatal morbidity and/or mortality. Our pri-
mary and secondary outcomes of interest are listed
below.
Primary outcomes
1. Maternal mortality (death during pregnancy or
within 42 days after termination of pregnancy)
2. Preterm delivery (delivery of a live-born baby before
37 completed weeks of gestation)
3. Perinatal mortality (stillbirth or neonatal mortality
(i.e., within 28 days after birth))
Secondary outcomes
1. Miscarriage (spontaneous abortion): fetal death
before 20 weeks gestational age
2. Preterm prelabor rupture of membranes (PPROM):
leakage of amniotic fluid in the absence of uterine
activity before 37 weeks gestation
3. Pregnancy-induced hypertension: onset of
hypertension (blood pressure ≥140/90 mmHg) in
the second half of pregnancy in the absence of
proteinuria or other markers of preeclampsia
4. Preeclampsia: hypertension and proteinuria
5. Clinical chorioamnionitis: clinical evidence of
intra-amniotic infection with or without laboratory
signs of infection
6. Histological chorioamnionitis: diagnosed by
histological examination of the placenta by a
pathologist [24]
7. Stillbirth (intrauterine death after 20 weeks of
gestation)
8. Very preterm delivery (delivery of a live-born baby
before 32 completed weeks gestation)
9. Low birth weight: birth weight of <2500 grams [25]
10.SGA: birth weight <10th centile for gestational age
11.Early onset neonatal sepsis: clinical evidence of
sepsis with laboratory signs of infection within 72 h
after delivery
12.Neonatal death: death of a baby occurring within the
first 28 days of life [26]
We will consider other adverse pregnancy outcomes
or composite outcomes for inclusion as relevant, empha-
sizing that these were not pre-defined.
Information sources
Two reviewers will independently search for eligible sys-
tematic reviews through the following electronic data-
bases (from inception): Cochrane Database of Systematic
Reviews (CDSR), MEDLINE (Pubmed), EMBASE, World
Health Organization (WHO), Global Health Library
(covers African Index Medicus (AIM), Latin American
and Caribbean Health Science Literature (LILACS),
Index Medicus for the Eastern Mediterranean Region
(IMEMR), Index Medicus for South-East Asia Region
(IMSEAR), Western Pacific Region Index Medicus
(WPRIM), and SciELO in addition to MEDLINE), and
Google Scholar. This search will be supplemented by a
search for unpublished, ongoing, or recently completed
systematic reviews in PROSPERO. In addition, reference
lists of included reviews will be screened to identify add-
itional eligible systematic reviews. We will check for
additional relevant articles by searching citations of eli-
gible reviews via Google Scholar.
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Search strategy
A draft search strategy was developed for MEDLINE
using medical subject headings (MeSH) and free text
keywords related to pregnancy, periodontal disease, and
systematic reviews (Additional file 2). The search strat-
egy will be adapted for use in other databases. We will
apply no restrictions to publication date or publication
status of the review. Reviews published in any language
will be eligible for inclusion.
Study records
Data management
All records identified will be uploaded or manually en-
tered into EndNote X4.0.2 reference management soft-
ware (Thomson Reuters, New York City, NY). We will
automatically and manually de-duplicate records. End-
Note will also be used during the selection process to
keep track of the reasons for exclusion at different stages
for presentation in the preferred reporting items for sys-
tematic review and meta-analysis (PRISMA) diagram.
Selection process
Two reviewers will independently screen titles and ab-
stracts of systematic reviews to assess eligibility for in-
clusion in this overview. After initial selection, full-text
reports of potentially eligible systematic reviews will be
obtained and screened to assess eligibility for final inclu-
sion in the overview. In case of identification of un-
published or ongoing studies, we will contact the
corresponding author for information on the current
status of the systematic review (ongoing versus com-
pleted) and whether any preliminary data may be in-
cluded in our overview. Disagreements will be resolved
through discussion and/or consultation of a third re-
viewer. Reviewers will not be blinded to journal titles,
study authors, or institutions.
Data collection process
Two reviewers will independently extract relevant data
from the included systematic reviews using a customized
data extraction form. The data extraction form will be
developed a priori and will be piloted using the first five
eligible reviews and amended where required based on
this pilot.
We will limit data extraction to the systematic reviews
included in this overview and not pursue in-depth evalu-
ation of the primary studies included in each systematic
review. If relevant information is missing, we will con-
tact authors of the included systematic reviews to re-
quest missing information.
The data items we will extract from each systematic
review are informed by the Cochrane Effective Practice
and Organization of Care checklist and the PRISMA
statement [27, 28]. We will extract bibliographic and ad-
ministrative data for each review, including author
names and institutions, journal, publication year, funding
sources and role of study sponsors, any conflicts of
interest reported, and registration details of the review
protocol, if applicable. We will extract the following data
relating to the report characteristics of each review: eligi-
bility criteria used, information sources used, the applied
search strategy including search periods, applied limita-
tions, and study selection methods. We will note the pri-
mary research questions and all outcomes for which
data was sought, including length of follow-up where ap-
plicable. We will also extract the following main results
of the review: the number of primary studies included,
study population characteristics, and type of controls. In
addition, for included systematic reviews that evaluated
an intervention, we will extract details on the interven-
tion(s) investigated: type of intervention, duration,
frequency, timing, deliverer, setting, and for pharmaco-
logical interventions: generic and trade name and dos-
age. We will note any reported adverse effects of
treatment. In case of meta-analysis having been con-
ducted, we will extract relevant methodological aspects,
as well as results of any meta-analyses, including sub-
group and sensitivity analyses. We will also extract
methodological details and results of any meta-bias as-
sessments (e.g., assessment of publication bias) having
been conducted. Finally, we will extract reported limita-
tions and overall conclusions of the review. Disagree-
ments during the data extraction process will be
resolved through discussion and/or consultation of a
third reviewer.
Risk of bias for systematic reviews
There is currently no gold standard for the assessment
of quality or risk of bias in overviews of systematic re-
views [29, 30]. The most commonly used tool to assess
the quality of systematic reviews included in overviews
of systematic reviews is the assessment of multiple sys-
tematic reviews (AMSTAR) checklist [29]. Two re-
viewers will independently appraise risk of bias of the
included systematic reviews using the validated
AMSTAR checklist [31, 32] by scoring each systematic
review with a maximum of 11 points. Disagreements will
be resolved through discussion and/or consultation of a
third reviewer. We plan to retain studies of any level of
risk of bias in our data synthesis. We will, however, in
our narrative synthesis consider risk of bias of individual
reviews when discussing our findings, focusing mainly
on the conclusions of the highest quality reviews.
Data synthesis
In a narrative synthesis, we will summarize the charac-
teristics and findings of the included systematic reviews
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using texts and tables to provide insight into the evi-
dence for an association between periodontal disease
and the evaluated outcome and, secondly, on how this
association might be affected by periodontal treatment
during pregnancy. The data extracted from the system-
atic reviews will be summarized and categorized accord-
ing to pregnancy outcome. We will report any outcomes
of interest for which no reviews were found.
We will not conduct a meta-analysis of meta-analyses.
Pooling the results of the included systematic reviews is
likely to introduce undesired bias as it will give dispro-
portionate statistical power to primary studies included
in more than one systematic review [33, 34].
Risk of bias across systematic reviews
To provide insight in the degree of overlap in the inclu-
sion of primary studies between systematic reviews, we
will generate a citation matrix that cross-links all sys-
tematic reviews (columns) with all the primary studies
included in the systematic reviews (rows) [34]. We will
quantify the degree of overlap (i.e., the repeated occur-
rences of the primary studies) by calculating the cor-
rected covered area (CCA) in this citation matrix [34].
To minimize publication bias, we aim to include all
relevant data from unpublished ongoing or completed
systematic reviews, as previously mentioned. To evaluate
selective reporting within systematic reviews, we will
compare outcomes reported in the systematic review
protocols (if available) and the published reports of the
systematic reviews. If a systematic review protocol is not
available, we will compare outcomes reported in the
methods and results sections of the published report of
the systematic review.
Confidence in cumulative estimate
We will explore the underlying reasons for any discrep-
ancies between studies, taking into account study design
characteristics and risk of bias. We will take these as-
pects into account when discussing the findings of our
overview and formulating our conclusions.
Discussion
This review will provide a synthesis of the existing sys-
tematic review literature on the association between
periodontal disease and adverse pregnancy outcomes, as
well as on the impact of interventions to prevent or treat
periodontal disease on these outcomes. To the best of
our knowledge, this will be the most comprehensive as-
sessment of the evidence in this field to date. We will
conduct and report our review using existing guidelines.
A limitation of this undertaking is that the design (i.e., a
review of reviews) precludes formulation of overall effect
estimates via meta-analysis. Based on our evidence syn-
thesis, we will formulate recommendations for clinicians
caring for preconceptional and pregnant women. In
doing so, our review has the potential to contribute to
reducing the significant global burden of adverse preg-
nancy outcomes. We will furthermore identify the key
knowledge gaps in the field and accordingly propose fu-
ture research priorities.
Ethics and dissemination
No formal ethical assessment or informed consent is re-
quired for the purpose of this study. In accordance with
the PRISMA-P recommendations [19, 20], our protocol
was registered with PROSPERO (http://www.crd.york.a-
c.uk/prospero/display_record.asp?ID=CRD42015030132)
on 9 December 2015 (CRD42015030132). The findings
of the study will be summarized in one or two manu-
scripts (i.e., one per research objective) to be submitted
for publication in an international peer-reviewed scien-
tific journal. In the event of amendments, reasons for
deviation from the protocol will be mentioned in the de-
finitive manuscript and will include a description of the
changes made accompanied by the date of each
amendment. Changes will not be incorporated into
the protocol.
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